Skip to main content

Table 1 Baseline data of LUAD patients according to the expression and proportion of the K-Ras4A isoform

From: Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients

Clinical parameters

Values

All patients

K-Ras4A expressiona

K-Ras4A proportionb

N (%)

High [N (%)]

Low [N (%)]

p-valuec

High [N (%)]

Low [N (%)]

p-value

Age

≥65

276 (53.5)

137 (26.6)

139 (26.9)

1.0

141 (27.3)

135 (26.2)

0.616

< 65

221 (42.8)

110 (21.3)

111 (21.5)

 

107 (20.7)

114 (22.1)

 

NAd

19 (3.7)

11 (2.1)

8 (1.6)

 

10 (1.9)

9 (1.9)

 

Gender

Male

238 (46.1)

119 (23.1)

119 (23.1)

1.0

117 (22.7)

121 (23.4)

0.791

Female

278 (53.9)

139 (26.9)

139 (26.9)

 

141 (27.3)

137 (26.6)

 

Smoking history

Yes

427 (82.8)

219 (42.4)

208 (40.3)

0.299

215 (41.7)

212 (41.1)

1.0

No

75 (14.5)

33 (6.4)

42 (8.1)

 

38 (7.4)

37 (7.2)

 

NA

14 (2.7)

6 (1.2)

8 (1.6)

 

5 (1.0)

9 (1.7)

 

KRAS amplificatione

Present

61 (11.8)

42 (8.1)

19 (3.7)

2.70E-3

30 (5.8)

31 (6.0)

1.0

Absent

455 (88.2)

216 (41.9)

239 (46.3)

 

228 (44.2)

227 (44.0)

 

KRAS mutations

Present

148 (28.7)

110 (21.3)

38 (7.4)

4.82E-12

101 (19.6)

47 (9.1)

2.49E-7

Absent

368 (71.3)

148 (28.7)

220 (42.6)

 

157 (30.4)

211 (40.9)

 

EGFR mutations

Present

45 (8.7)

12 (2.3)

33 (6.4)

1.81E-3

14 (2.7)

31 (6.0)

0.0125

Absent

471 (91.3)

246 (47.7)

225 (43.6)

 

244 (47.3)

227 (44.0)

 

Pathological stage

I

276 (53.5)

125 (24.2)

151 (29.3)

0.0460

128 (24.8)

148 (28.7)

0.0327

II

122 (23.6)

66 (12.8)

56 (10.9)

 

58 (11.2)

64 (12.4)

 

III

84 (16.3)

52 (10.1)

32 (6.2)

 

54 (10.5)

30 (5.8)

 

IV

26 (5.0)

13 (2.5)

13 (2.5)

 

14 (2.7)

12 (2.3)

 

NA

8 (1.6)

2 (0.4)

6 (1.2)

 

4 (0.8)

4 (0.8)

 
  1. aMedian value (3.41 TPM) of K-Ras4A expression levels was used to divide LUAD patients into two groups
  2. bMedian value (0.1659) of K-Ras4A proportions was used to divide LUAD patients into two groups
  3. cChi square tests were used to examine the relationship between the nominal variables
  4. dNA, Not available
  5. eThe presence or absence of KRAS amplification were defined to 10% or more KRAS amplified or not